Upadacitinib for Giant-Cell Arteritis, SELECT-GCA Trial Results
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Upadacitinib for Giant-Cell Arteritis, SELECT-GCA Trial Results
-
Narrated by:
-
By:
About this listen
This is a research article from the New England Journal of Medicine detailing the findings of the SELECT-GCA clinical trial, which investigated a potential new treatment for giant-cell arteritis. The trial randomly assigned patients to receive either upadacitinib at different doses or a placebo, in combination with a glucocorticoid taper. The results indicated that a 15 mg dose of upadacitinib was more effective than placebo in achieving sustained remission and reducing glucocorticoid exposure. The study also reviewed the safety profile of upadacitinib in this patient population.
What listeners say about Upadacitinib for Giant-Cell Arteritis, SELECT-GCA Trial Results
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.